Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Oscar B. Lahoud"'
Autor:
Oscar B. Lahoud, Heather Landau, James Nguyen, Sean Devlin, Nikoletta Lendvai, Jonathan Weltz, Tumininu Ayorinde, David J. Chung, Alexander M. Lesokhin, Tarun Kewalramani, Neha Korde, Sham Mailankody, Ola Landgren, Sergio Giralt, Raymond L. Comenzo, Hani Hassoun
Publikováno v:
Leukemialymphoma. 63(9)
Although upfront autologous stem cell transplantation (ASCT) generally improves progression-free survival (PFS) in newly diagnosed multiple myeloma (NDMM), the overall survival (OS) benefit and optimal timing of ASCT are not well established. Patient
Autor:
Anthony R. Mato, Doris M. Ponce, Esperanza B. Papadopoulos, Oscar B Lahoud, Lindsey E. Roeker, Andrew D. Zelenetz, Sean M. Devlin, Juliet N. Barker, Boglarka Gyurkocza, Parastoo B. Dahi, James W. Young, Guenther Koehne, Sergio Giralt, Molly Maloy, Craig S. Sauter, Ann A. Jakubowski, Miguel Perales, Hugo Castro-Malaspina
Publikováno v:
Blood Adv
Allogeneic hematopoietic stem cell transplantation (HSCT) may potentially cure patients with chronic lymphocytic leukemia (CLL) and Richter’s transformation (CLL-RT) or CLL without RT, but the impact of novel agents on HSCT is unclear. CLL-RT patie
Autor:
Michael Scordo, Gunjan L. Shah, Peter A. Adintori, Andrea Knezevic, Sean M. Devlin, Marissa L. Buchan, Elaina V. Preston, Andrew P. Lin, Natasia T. Rodriguez, Caroline A. Carino, Linh K. Nguyen, Nancy Cruz Sitner, Andrei Barasch, Mark G. Klang, Molly A. Maloy, Brooke Mastrogiacomo, Dean C. Carlow, Ryan C. Schofield, Ann E. Slingerland, John B. Slingerland, Christoph K. Stein‐Thoeringer, Oscar B. Lahoud, Heather J. Landau, David J. Chung, Marcel R.M. van den Brink, Jonathan U. Peled, Sergio A. Giralt
Publikováno v:
Cancer
Dysgeusia is a common but understudied complication in patients undergoing autologous hematopoietic cell transplantation (auto-HCT). We assessed the feasibility of using chemical gustometry (CG) to measure dysgeusia and explored its associations with
Autor:
Malin Hultcrantz, Even H. Rustad, Venkata Yellapantula, Allison Jacob, Theresia Akhlaghi, Neha Korde, Sham Mailankody, Alexander M. Lesokhin, Hani Hassoun, Eric L. Smith, Oscar B. Lahoud, Heather J. Landau, Gunjan L. Shah, Michael Scordo, David J. Chung, Sergio Giralt, Elli Papaemmanuil, Ola Landgren
Publikováno v:
Clin Cancer Res
Purpose: Minimal residual disease (MRD) negativity is a strong predictor for outcome in multiple myeloma. To assess V(D)J clonotype capture using the updated Adaptive next-generation sequencing (NGS) MRD assay in a clinical setting, we analyzed basel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::447ef54abec3392749e494e70ddfa81f
https://europepmc.org/articles/PMC9179004/
https://europepmc.org/articles/PMC9179004/
Autor:
Ahmet Dogan, Heiko Schöder, Oscar B Lahoud, Santosha Vardhana, Theresa Davey, Craig H. Moskowitz, Anita Kumar, M. Lia Palomba, Brielle Liotta, Paul A. Hamlin, Beatriz Wills Sanin, Colette Owens, William T. Johnson, Joachim Yahalom, Matthew J. Matasar, Connie Lee Batlevi, Christina R. Lee, Alayna Santarosa, Helen Hancock, Lorenzo Falchi, Esther Drill, Audrey Hamilton, Alison J. Moskowitz, Samia Sohail, Rachel Neuman, Gunjan L. Shah, Sunyoung Ryu, Natasha Galasso, David J. Straus, Gilles Salles, Georgios Pongas, William Blouin, Steven M. Horwitz, Ariela Noy, Erel Joffe, Ildefonso Rodriguez-Rivera, Andrew D. Zelenetz, Andrew M. Intlekofer, Gottfried von Keudell, Nivetha Ganesan, Philip Caron, Leslie Perez
Publikováno v:
J Clin Oncol
PURPOSE We conducted a phase II study evaluating pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin (pembro-GVD) as second-line therapy for relapsed or refractory (rel/ref) classical Hodgkin lymphoma (cHL) (ClinicalTrials.gov iden
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9666753bc8fb50bed83326e0a6db7606
https://europepmc.org/articles/PMC9851707/
https://europepmc.org/articles/PMC9851707/
Autor:
Parastoo B. Dahi, Andrew Lin, Michael Scordo, Jessica R. Flynn, Sean M. Devlin, Josel D. Ruiz, Lauren DeRespiris, Dean Carlow, Christina Cho, Oscar B. Lahoud, Miguel-Angel Perales, Craig S. Sauter, Jan Jaap Boelens, Rick Admiraal, Sergio A. Giralt, Gunjan L. Shah
Publikováno v:
Transplantation and Cellular Therapy. 28:485.e1-485.e6
High-dose melphalan is one of the main cytotoxic DNA alkylating agents and is used in many transplantation conditioning regimens. Studies have shown a wide range of drug exposure when a traditional weight-based dose of melphalan is used. The optimal
Autor:
Hillard M. Lazarus, Minoo Battiwalla, Jean A. Yared, Baldeep Wirk, Robert Peter Gale, Ibrahim Ahmed, Marcelo C. Pasquini, Sachiko Seo, Bipin N. Savani, Leona Holmberg, Richard T. Maziarz, Gerhard C. Hildebrandt, Richard F. Olsson, Nelli Bejanyan, Shahinaz M. Gadalla, Mingwei Fei, Kehinde Adekola, Mahmoud Aljurf, Oscar B Lahoud, Jeffrey Auletta, Seth J. Rotz, Vaibhav Agrawal, Claudio G. Brunstein, Jan Cerny, Soyoung Kim, Shin Mineishi, Vikram Mathews, Harry C. Schouten, Siddhartha Ganguly, Cesar O. Freytes, Miguel-Angel Perales, Joseph S. Bubalo, Peiman Hematti, Maxim Norkin, Ran Reshef, Marcos de Lima, Taiga Nishihori, Stefan O. Ciurea, John Rogosheske, Heather Landau, Lynette Chee, Shahrukh K. Hashmi
Publikováno v:
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, vol 25, iss 3
Biology of Blood and Marrow Transplantation, 25(3), 480-487. Elsevier Science
Biology of Blood and Marrow Transplantation, 25(3), 480-487. Elsevier Science
Data are limited on whether to adjust high-dose chemotherapy before autologous hematopoietic cell transplant (autoHCT) in obese patients. This study explores the effects of dose adjustment on the outcomes of obese patients, defined as body mass index
Autor:
Michael Scordo, Lakshmi V. Ramanathan, Heather Landau, Kazunori Murata, Eric L. Smith, Sean M. Devlin, Sydney X. Lu, Hani Hassoun, Urvi A Shah, Gunjan L. Shah, Ola Landgren, Caleb Ho, Neha Korde, Benjamin Diamond, Ahmet Dogan, Sham Mailankody, Carlyn Tan, Oscar B Lahoud, Kylee H Maclachlan, Tim J Peterson, Maria E. Arcila, David J. Chung, Andriy Derkach, Katie L. Thoren, Francesco Maura, Alexander M. Lesokhin, Even H Rustad, Sergio Giralt, Mikhail Roshal, Malin Hultcrantz
Publikováno v:
The Lancet. Haematology. 8(6)
Background Lenalidomide maintenance improves progression-free survival for patients with multiple myeloma, although its optimal duration is unknown. Clearance of minimal residual disease (MRD) in the bone marrow results in superior outcomes, although
Autor:
Michael Scordo, Heather Landau, Minal Patel, Alvin Makohon-Moore, Juan S. Medina-Martinez, Ola Landgren, Lance Zhang, David J. Chung, Benjamin Diamond, Ahmet Dogan, Gunes Gundem, Sergio Giralt, Elli Papaemmanuil, Eric Alden Smith, Venkata Yellapantula, Patrick Blaney, Alexander M. Lesokhin, Cody Ashby, Gary A. Ulaner, Neha Korde, Oscar B Lahoud, Frits van Rhee, Yangyu Zhou, Christine A. Iacobuzio-Donahue, Max Levine, Kylee H Maclachlan, Francesco Maura, Yanming Zhang, Urvi A Shah, Even H Rustad, Priscilla Baez, Sham Mailankody, Eileen M Boyle, Sydney Lu, Rajya Kappagantula, Juan E. Arango Ossa, Hani Hassoun, Gunjan L. Shah, Jonathan U. Peled, Marc A. Attiyeh, Gareth J. Morgan, Malin Hultcrantz
Publikováno v:
Nature Communications
Nature Communications, Vol 12, Iss 1, Pp 1-1 (2021)
Nature Communications, Vol 12, Iss 1, Pp 1-1 (2021)
Multiple myeloma (MM) progression is characterized by the seeding of cancer cells in different anatomic sites. To characterize this evolutionary process, we interrogated, by whole genome sequencing, 25 samples collected at autopsy from 4 patients wit
Autor:
Alexandra, Gomez-Arteaga, Gunjan L, Shah, Raymond E, Baser, Michael, Scordo, Josel D, Ruiz, Adam, Bryant, Parastoo B, Dahi, Arnab, Ghosh, Oscar B, Lahoud, Heather J, Landau, Ola, Landgren, Brian C, Shaffer, Eric L, Smith, Guenther, Koehne, Miguel-Angel, Perales, Sergio A, Giralt, David J, Chung
Publikováno v:
Biol Blood Marrow Transplant
Allogeneic hematopoietic cell transplantation (alloHCT) for multiple myeloma (MM), with its underlying graft-versus-tumor capacity, is a potentially curative approach for high-risk patients. Relapse is the main cause of treatment failure, but predict